#465: Why Good Medical Devices Fail: Reimbursement Strategy with Ali Samiian

In this episode, host Etienne Nichols sits down with Ali Samiian, founder and managing principal of Popular Access Advisors, to demystify the critical and often misunderstood world of MedTech reimbursement. Far too many early-stage medical device companies treat reimbursement as a secondary, post-launch paperwork exercise, only to find that their brilliant, FDA-cleared technology fails because no one has figured out who will pay for it. Ali draws on his 20-plus years of experience in market access, health economics, and executive leadership to explain why reimbursement must be treated as a core product strategy long before submission.

The conversation explores how commercialization pathways are inherently dictated by the site of care—whether inpatient, outpatient, or home use. Ali highlights common and costly pitfalls, such as designing clinical trials solely for FDA clearance while neglecting the specific evidence endpoints that insurance payers demand. Payers do not just look at safety and efficacy; they look at long-term clinical value, accessibility, durability, and standard-of-care comparisons. Using practical, real-world examples, Ali demonstrates how simple adjustments to product design and clinical study lengths can proactively align a device with existing or novel code requirements.

Finally, the episode highlights the shifting regulatory landscape and new initiatives designed to accelerate market access for breakthrough innovations. Etienne and Ali discuss the FDA’s Total Lifecycle Product Advisory (TAP) program and the emerging CMS Regulatory Alignment for Predictable and Immediate Device (RAPID) program. By understanding these frameworks and embedding payer-relevant outcomes into early-stage research, innovators can significantly compress their revenue cycles, avoid product redesigns, and successfully deliver life-changing technologies into the hands of patients.

Key Timestamps

• 00:03 - Introduction to MedTech reimbursement and guest Ali Samiian.
• 01:46 - The difference between clearing the FDA bar and achieving commercial success.
• 02:16 - Case Study: How product design and classification categories impact commercialization.
• 03:45 - The risk of ignoring durable medical equipment (DME) requirements during design.
• 05:22 - Categorizing sites of care: Inpatient, outpatient, ASCs, and home use (DMEPOS).
• 06:15 - Mistake #1: Postponing reimbursement strategy until after FDA approval.
• 07:35 - Mistake #2: Designing clinical studies for the FDA without considering payer-relevant endpoints.
• 09:02 - Understanding standard of care, durability data, and minimizing study bias for payers.
• 10:30 - Exploring the FDA's TAP program and the new CMS RAPID program for breakthrough devices.
• 12:15 - Mistake #3: Rushing regulatory pathways without assessing commercial and price-point implications.
• 13:50 - Identifying stakeholders and understanding the oblique nature of CMS and payer regulations.
• 14:38 - Deconstructing how to build new codes and establish premium pricing from scratch.

Quotes"Clearing the FDA bar is not really what gets us to commercialization. We need to have product and clinical differentiation... A lot of reimbursement is actually more of a strategy exercise." - Ali Samiian"The FDA basically looks at is the product safe and effective? Payers look at is there value and is there accessibility for the product?" - Ali SamiianTakeaways

• Incorporate Payer Endpoints Early: MedTech innovators should involve a reimbursement advisor during clinical trial design to incorporate payer-relevant endpoints (like durability and standard-of-care comparisons), avoiding the need for an expensive second study.
• Align Design with Code Descriptors: Ensure product features and testing durations match the strict regulatory definitions of your target site of care (e.g., verifying a home-use device meets the three-year durability testing threshold for DME classification).
• Evaluate Pathways Holistically: Assess regulatory pathways (510(k) vs. De Novo vs. PMA) not just by upfront cost or speed to market, but by their long-term implications on pricing, coding, and time-to-reimbursement.
• Leverage Breakthrough Programs: Companies with breakthrough device designation should actively follow and align with collaborative initiatives like the FDA's TAP and CMS's RAPID programs to secure immediate coverage upon clearance.

References

• FDA TAP Program: The Total Lifecycle Product Advisory program designed to provide early, strategic communication with senior FDA leadership for breakthrough devices.
• CMS RAPID Program: Regulatory Alignment for Predictable and Immediate Device program, an initiative aimed at accelerating coverage pathways for breakthrough innovations.
• Etienne Nichols: Connect with the host on LinkedIn.

MedTech 101 Section

• Reimbursement vs. FDA Clearance: Think of FDA clearance as getting a driver's license—it proves your device is safe to be on the road. Reimbursement is like getting a toll pass; it determines who is actually going to pay for the journey so you can keep driving.
• Durable Medical Equipment (DME): This is a category of medical equipment used in the home that can withstand repeated use. Think of it like a sturdy pair of boots—if it isn't designed and tested to last a specific number of years (usually three), payers won't classify it as DME, even if it works perfectly.
• The "Cup" Analogy for Coding: Payers view similar items as identical commodities. A cup is a cup, whether it holds coffee or tea, and they want to pay one standard price for it. To get paid more, an innovator must prove their "cup" has unique technology that provides a fundamentally different, meaningful clinical outcome—like a cup that mechanically prevents spills for patients with tremors.

Feedback Call-to-Action

We love hearing from our community of MedTech innovators! Do you have thoughts on this episode, questions about market access, or suggestions for future topics? Reach out to us directly at podcast@greenlight.guru. Every email is read by our team, and we look forward to providing you with a personalized response.

Sponsors

This episode is brought to you by Greenlight Guru, the only dedicated medical device success platform. Moving from product development to commercial adoption requires absolute precision in data and compliance. Greenlight Guru helps medical device teams smoothly bridge the gap between regulatory approval and commercialization. By integrating both Quality Management Software (QMS) and Electronic Data Capture (EDC) solutions, Greenlight Guru ensures your clinical trial data is flawlessly captured to satisfy the FDA, while keeping your quality systems audit-ready for commercial scaling. Learn more at www.greenlight.guru.